University of Medicine and Pharmacy, Clinical Science-Internal Medicine, Gheorghe Marinescu 38, Tirgu Mureș 540139, Romania.
University of Medicine and Pharmacy "Iuliu Hațieganu", Department of Medical Informatics and Biostatistics, Louis Pasteur St, no. 6, 400349 Cluj-Napoca, Romania.
Eur J Intern Med. 2017 Oct;44:62-66. doi: 10.1016/j.ejim.2017.05.017. Epub 2017 May 31.
Preventive strategies developed to avoid the complications of antiplatelet therapies recommend the evaluation of risk factors for gastrointestinal events and indicated gastroprotective strategies.
We aimed to assess the impact of predisposing factors - histological findings, concomitant drug consumption, comorbidities, symptoms, social habits, Helicobacter pylori infection - on severe gastro-duodenal lesions in patients with low-dose aspirin and concomitant protective therapy with proton pump inhibitors (PPI).
We enrolled 237 patients with LDA and PPI therapy, referred for upper digestive endoscopy, divided into two groups according to the severity of their endoscopic lesions (172 patients with no or mild endoscopic lesions and 65 patients with severe endoscopic lesions).
In the univariate logistic regression model, the factors associated with severe gastro-duodenal lesions were gender (OR=1.87, 95% CI: 1.04-3.41), anticoagulants (OR=2.40, 95% CI: 1.26-4.53), gastric atrophy and/or intestinal metaplasia (OR=1.85, 95% CI: 1.04-3.32), congestive heart failure (OR=2.59, 95% CI: 1.16-6.62), anaemia (OR=3.01, 95% CI: 1.67-5.47) and smoking (OR=4.29, 95% CI: 1.57-12.32). In the final model, anticoagulants (p=0.041<0.05) and anaemia (p=0.019<0.05) were risk factors for severe lesions via multivariate regression analysis, while for active/inactive chronic gastritis and smoking a positive dependency with a tendency towards statistical significance (p<0.10) was noticed for severe gastric lesions.
In patients treated with low-dose aspirin and gastroprotective therapy with proton pump inhibitors we have enough evidence to consider co-treatment with anticoagulants and anaemia important predictors for severe endoscopic lesions, while other factors such as inflammation in gastric biopsies, congestive heart failure, co-treatment with clopidogrel and smoking tended to have a positive influence on risk for severe gastro-duodenal lesions.
为避免抗血小板治疗的并发症而制定的预防策略建议评估胃肠道事件的危险因素,并采用适当的胃保护策略。
我们旨在评估易患因素(组织学发现、同时使用的药物、合并症、症状、社会习惯、幽门螺杆菌感染)对接受低剂量阿司匹林和质子泵抑制剂(PPI)保护治疗的患者发生严重胃十二指肠病变的影响。
我们纳入了 237 例接受 LDA 和 PPI 治疗的患者,因上消化道内镜检查而就诊,根据内镜下病变的严重程度将他们分为两组(172 例内镜下无或轻度病变,65 例内镜下严重病变)。
在单因素逻辑回归模型中,与严重胃十二指肠病变相关的因素为性别(OR=1.87,95%CI:1.04-3.41)、抗凝剂(OR=2.40,95%CI:1.26-4.53)、胃萎缩和/或肠化生(OR=1.85,95%CI:1.04-3.32)、充血性心力衰竭(OR=2.59,95%CI:1.16-6.62)、贫血(OR=3.01,95%CI:1.67-5.47)和吸烟(OR=4.29,95%CI:1.57-12.32)。在最终模型中,抗凝剂(p=0.041<0.05)和贫血(p=0.019<0.05)是严重病变的多因素回归分析的危险因素,而对于活动性/非活动性慢性胃炎和吸烟,严重胃病变存在阳性相关性且有统计学意义的趋势(p<0.10)。
在接受低剂量阿司匹林和质子泵抑制剂胃保护治疗的患者中,我们有足够的证据认为同时使用抗凝剂和贫血是严重内镜下病变的重要预测因素,而其他因素,如胃活检中的炎症、充血性心力衰竭、同时使用氯吡格雷和吸烟,可能对严重胃十二指肠病变的风险有积极影响。